While the past decade presented us with significant biotech and pharmaceutical advances, the future of the industry looks even more promising due to a few key focus areas that are predicted to lead the market in 2020, including oncology, cell and gene therapies, and real-world evidence.

TD2 President and CEO Stephen Gately recently spoke to BioSpace about industry-defining trends, such as immuno-oncology research and traditional targeted therapies, that are anticipated to continue well into the coming years and shape the industry landscape. Not only that, according to Gately, there could be a shift in how clinical trials are organized based on economic incentives. Read the full article here to learn more.

Probiotics in focus: How does L. reuteri affect gut health?

The composition of our intestinal microbiota, may be a measure of our overall health. The presence of an imbalance in the microbial gut community is...

Read more +

CAR T-cell Program Development: Key Considerations

For decades, the foundations of cancer treatment have been surgery, chemotherapy, and radiation therapy. However, these treatments are not always...

Read more +

Efficient Data Management: One Way to Expedite the Clinical Development Proces

Debates on the safety and effectiveness of vaccines have captured the public’s attention recently. A vaccine is a preventative strategy for certain...

Read more +

GET STARTED

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.

Skip to content